Pharmaceutical company Neos Therapeutics has entered into a licence agreement with Shire under which Neos has been granted a non-exclusive licence to certain patents.
According to a US Securities and Exchange Commission filing on Monday, March 6, the licence agreement centres on Neos’s NT-0201 (amphetamine extended-release oral suspension drug), a treatment for attention deficit hyperactivity disorder.
Before the licensing deal, Neos had filed a New Drug Application (NDA) with the Food and Drug Administration, asserting that Shire’s patents were invalid and would not be infringed.
Under the agreement, Neos is required to pay a lump sum of less than $1 million, no later than 30 days after receiving approval of the NDA.
The agreement also contains a covenant from Shire that it will not file a patent infringement lawsuit against Neos alleging that NT-0201 would infringe the Shire patents.
Read Full Article Here